---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-26-000051"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:27:45.011146+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Axogen Q1 revenue $61.5M (+27% YoY); raises FY 2026 revenue guidance to at least $270M

## Summary
- Q1 revenue $61.5M, up 26.6% YoY; gross margin expanded to 75.2% from 71.9%.
- GAAP net loss $19.6M ($0.38/share); adjusted net income $4.1M ($0.07/share) vs adjusted net loss $0.9M in Q1 2025.
- Raises full-year 2026 revenue guidance to at least 20% growth or $270M; expects gross margin 74%-76% and positive free cash flow.
- Closed upsized public offering netting $133.3M; used $69.7M to repay Oberland loan; cash & investments rose to $103.6M.
- Received positive coverage decisions from Cigna and Elevance Health; CMS new Level 3 Nerve Procedure Code boosts Avance reimbursement.

## SEC filing metadata
- accession: 0000805928-26-000051
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592826000051/0000805928-26-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592826000051/axgn-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-26-000051
- JSON: https://secwatch.observer/filing/0000805928-26-000051.json
- Plain text: https://secwatch.observer/filing/0000805928-26-000051.txt

## Key facts
- Earnings Releases
  Axogen, Inc. reported first quarter ended March 31, 2026 results: revenue $61.5 million, net income Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share, EPS $0.38 per share. Guidance raised.
  - Period: first quarter ended March 31, 2026
  - Revenue: $61.5 million
  - Net income: Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share
  - EPS: $0.38 per share
  - Guidance: raised
  - Result: reported results
  source text: Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter Financial Results • First quarter 2026 revenue was $61.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592826000051/0000805928-26-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.